Form 4 for STLN Starling Oncology, Inc.
Accepted 2025-05-22 00:00:00 ET · period of report 2025-05-21 · accession 0001628280-25-027205 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-05-22 | 2025-05-21 | STLN | Carter Robert Ross | CFO | D - Sale to Iss | $2.68 | -1,601 | 235.2K | -0.7% | -$4,291 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Class A Common Stock | 2025-05-21 | D | D | 1,601 | $2.68 | 235,174 | D | — | — | (F1) The sales reported in this Form 4 were effected to cover tax withholding obligations in connection with the vesting of restricted stock units (RSUs) pursuant to a sell-to-cover provision included in the RSU Agreement. |